Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

686
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Energy costs of Hannibal's alpine crossing.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Food web complexity underlies biodiversity effects on ecosystem functioning.

Nature·2026
Same author

Tinea barbae following ruxolitinib cream application in a vitiligo patient: a case report.

Frontiers in medicine·2026
Same author

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026
Same author

Space-use by feral cattle and horses shapes vegetation structure in a trophic rewilding area.

Ecological applications : a publication of the Ecological Society of America·2026
Same author

Real-Life Perception of Treatment Effectiveness After 24 Weeks of Topical Ruxolitinib in Non-Segmental Vitiligo: Insights From Patient-Reported Outcomes.

International journal of dermatology·2026

Related Experiment Video

Updated: Jun 12, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K

Update on primary cutaneous T-cell lymphomas rare subtypes.

Silvia Alberti-Violetti1,2, Emilio Berti3

  • 1Dermatology Unit, IRCCS Ca'Granda - Ospedale Maggiore Policlinico, Milan.

Dermatology Reports
|September 19, 2024
PubMed
Summary

Rare cutaneous T-cell lymphomas (CTCL) are now distinct entities in the WHO classification. This review summarizes their characteristics and potential treatments for better understanding and management.

Keywords:
T follicular helper phenotypeaggressive lymphomacutaneous lymphomarare cutaneous lymphoma

More Related Videos

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

468

Related Experiment Videos

Last Updated: Jun 12, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

468

Area of Science:

  • Dermatology
  • Hematology
  • Oncology

Background:

  • Rare subtypes of cutaneous T-cell lymphomas (CTCL) were previously provisional.
  • These entities are now recognized as distinct in the 5th World Health Organization classification.

Purpose of the Study:

  • To provide an updated summary of rare CTCL subtypes.
  • To focus on clinical, histological, and genomic characteristics.
  • To review classification and potential treatment strategies.

Main Methods:

  • Literature review of clinical, histological, and genomic data.
  • Analysis of the 5th World Health Organization classification of hematolymphoid tumors.
  • Synthesis of current knowledge on rare CTCL subtypes.

Main Results:

  • Four rare CTCL subtypes are now distinct entities: primary cutaneous γδ T-cell lymphoma, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorders, and primary cutaneous acral CD8+ T-cell lymphoma.
  • Updated information on the classification of these uncommon lymphomas is presented.
  • Current understanding of their clinical, histological, and genomic features is summarized.

Conclusions:

  • The 5th WHO classification formally recognizes these rare CTCL subtypes.
  • Further research into their specific characteristics is warranted.
  • This review provides a foundation for exploring targeted treatment strategies.